Category: Cannabis

Blinc Secures Patent for Branding Technology

Photo: The Blinc Group
The Blinc Group has secured a patent for its RingSystem hardware branding and labeling technology.
“Cannabis businesses have been struggling to maintain the proper amount of inventory in the vape space while also keeping their customers informed of what’s in their product,” said Sasha Aksenov, co-founder and chief innovation officer of The Blinc Group, in a statement.
“Companies shell out thousands of dollars for packaging and fill their cartridges with a specific cultivar to shortly find out that it’s not selling as expected. They are left with huge losses in branded hardware, but our Ring System allows the brands and licensed producers to label their products on demand during production, and, if they have to—pivot and relabel for pennies, not dollars.”
The Ring System consists of two bands one at the base of the mouthpiece or “top” and the other at the base of the cartridge—Top Ring and Base Ring. Before capping a compatible cartridge or disposable, operators can snap the Top Ring onto the mouthpiece of the cartridge with the strain name. The ring is also easily removed if the strain is not being sold or brands decide to pivot on the formulation or experience.
“At the Blinc Group we strive every day to promote innovation, quality, safety, and integrity in every one of our products, the Ring System is no different. It is imperative that the entire industry take those goals to heart,” said Arnaud Dumas de Rauly, co-founder & CEO of The Blinc Group. “Consumers need to know what’s in their cartridges at all times and for this industry to thrive companies need to be able to increase their productivity and flexibility, without spending huge amounts of working capital on an unsold inventory. There are enough hurdles in the cannabis space, what’s in your vape cartridge shouldn’t be one of them.”
April 17, 2022
U.S. House votes to decriminalize marijuana

Photo: p_gangler
The U.S. House of Representatives voted on April 1 to decriminalize marijuana at the federal level, reports The New York Times.
While the Marijuana Opportunity Reinvestment and Expungement Act is unlikely to get the required majority in the Senate, supporters said the vote was a necessary step toward building consensus on something that can become law.
The bill would remove marijuana from the federal government’s list of controlled substances, impose an 8 percent tax on cannabis products, allow some convictions on cannabis charges to be expunged and press for sentencing reviews at the federal and state levels. It would also make Small Business Administration loans and services available to cannabis businesses while setting standards for them.
By lowering law enforcement and incarceration costs and imposing new taxation, the bill would save the government hundreds of millions of dollars. The Congressional Budget Office estimated that the act would reduce the federal deficit by nearly $3 billion over the next decade.
Thirty-seven states have legalized cannabis for medical use, and 15 have granted adults legal access for purely recreational purposes. Because cannabis remains a federally controlled substance, however, banks insured by the federal government have been loath to make their services available to the burgeoning marijuana industry.
Faced with declining demand for cigarettes, some tobacco companies have been eying marijuana as a new business area.
Sales in that industry totaled $20 billion in 2020 and are projected to more than double by 2025.
April 4, 2022
Cannabis Research Breakthrough

Photo: Elroi
22nd Century Group and KeyGene say they have made a breakthrough in hemp/cannabis plant research leading to the successful transformation of the hemp/cannabis plant genome using a proprietary plant transformation and regeneration technology and clear protein expression by the introduced genes.
“I cannot emphasize enough what an enormous achievement it is for our company to have cracked the code to show proof of genome transformation in the hemp/cannabis plant. This is the holy grail in plant science and places us in a commanding leadership position in the race to secure patents and other valuable intellectual property in the emerging hemp/cannabis genetics field,” said James A. Mish, CEO of 22nd Century Group, in a statement.
“These newest plant transformation discoveries unlock additional revenue opportunities for the company and accelerate our efforts to create new hemp/cannabis plant lines with much higher commercial value at accelerated rates, lower cost and lower risk to our customers.”
The plant transformation breakthrough unlocked by 22nd Century and KeyGene enables the desired DNA sequences to be inserted directly into or created from a plant’s existing genetic material, creating a more expedient and focused methodology to achieve the desired outcome.
In addition to its transformation capability, 22nd Century Group has exclusive access to a battery of gene-editing capabilities, based on meganuclease technology, directed to seven of the key enzymes for the biosynthesis of cannabinoids plus four patent families that cover vital enzymes. Unlike other more widely available gene-editing technologies like CRISPR-CAS-9, this technology is allowed for use in cannabis.
The breakthrough gene-editing and transformation technology will allow 22nd Century Group to target specific hemp/cannabis biosynthesis pathways and expand the ability to engineer the modification of cannabinoids in plants.
February 23, 2022
Pyxus Exits Canadian Cannabis Operations

Photo: Pyxus International
Pyxus International has completed the sale of assets of FIGR Norfolk, the final key step in the company’s strategic decision to exit its cash flow negative cannabinoid operations.
With the completion of this sale, which occurred on Jan. 28, 2022, no subsidiaries of the company produce or sell Canadian cannabis in any capacity. In addition, the company is no longer involved in activities related to industrial hemp or CBD.
“Since announcing our intention to focus on tobacco and e-liquids last year, we have made tremendous strides in streamlining our operations and reducing our SG&A costs,” said Pieter Sikkel, president and CEO of Pyxus International, in a statement. “Moving forward, we will continue to focus on our tobacco-related businesses while leveraging the company’s strengths in agronomy, traceability and sustainability in order to deliver value to our stakeholders.”
February 10, 2022
State of Euphoria

Photos courtesy of Demecan and the German Cannabis Association
Germany’s new government plans to legalize cannabis.
By Stefanie Rossel
With Germany’s new government, a coalition of the center-left Social Democrats, the Green party and the liberal Free Democrats, taking office on Dec. 6, 2021, a long-awaited change moved closer to becoming reality. The country, the parties announced in their coalition agreement, will legalize the sale of cannabis to adults—that is, consumers from the age of 18—for recreational purposes. Although no details were mentioned and no timetable was set, the announcement sent cannabis stocks to new heights.
The Financial Times described the announcement as “game-changing precedent for the global business of growing and selling marijuana” that would be closely watched by other countries. With its proposal, Germany would join a movement of cannabis reform around the world. Canada, Uruguay as well as 19 U.S. states and the District of Columbia have already legalized recreational cannabis. In the European Union, Malta in mid-December became the first country to permit the use and growth of weed for recreational purposes. Sales, however, will remain prohibited.
After legalization, Germany will be the biggest EU cannabis market by far. For the time being, the recreational consumption of marijuana in the country is not explicitly illegal, but sales, imports and cultivation are prohibited. Germany legalized medicinal cannabis in 2017.
With further legalization, the government aims to dry out the illegal market, lower criminal justice expenditures and protect public health. According to the German Cannabis Association, illegal marijuana is often contaminated with sand, sugar, glass or spices. Increasingly, synthetic cannabinoids, up to 100 times stronger than natural psychoactive cannabinoids, are used to dilute the weed.
The proposal also includes preventive measures, such as the creation of facilities where consumers can check cannabis from the black market for harmful additives. Marijuana advertising will be strictly regulated. The coalition has agreed to keep the ban on private cannabis cultivation. Whether foreign nationals will be allowed to buy cannabis in Germany, too, remains unclear. According to the coalition agreement, the measure will be evaluated after four years, especially in terms of youth protection.

Georg Wurth
Details Unknown
What cannabis regulation in Germany will look like exactly remains unclear. The coalition is expected to introduce a cannabis tax; a recent study by Heinrich Heine University Duesseldorf estimates that such a tax could contribute €1.8 billion ($1.14 billion) annually to the state treasury. Legalization would bring in an estimated €4.7 billion per year due to additional revenues from corporate tax, trade tax and value-added tax as well as from savings in prosecution and the judicial system. It could also create 27,000 new jobs, the study found.
Apart from pharmacies, the licensed dispensaries mentioned in the coalition agreement reportedly might include tobacconist shops and perhaps even dedicated coffee shops as in the Netherlands, which tolerates recreational cannabis for personal consumption. The new government is expected to define thresholds for the content of tetrahydrocannabinol (THC), the psychoactive ingredient in cannabis, in the products to be sold. The government might also review Germany’s traffic laws, which currently allow 1 nanogram of THC per milliliter of blood serum.
The legalization proposal, long opposed by previous Christian Democrat party-led governments, has triggered a heated debate in Germany. Physicians specializing in addiction treatment warn that it would boost consumption and encourage related issues, such as dependence, depressive and anxiety disorders, psychoses and developmental delays in young people. Meanwhile, law enforcement officials are skeptical that legalization will erase the black market. A tax, they claim, would make legal cannabis significantly more expensive, thus leading to competition between legal and illegal sources.
Georg Wurth, managing director of the German Cannabis Association, does not share law enforcement’s concerns. “The black market will at least be pushed back,” he says. “Every single euro of revenue that will be generated on the legal market will be retracted from the illicit market, and every percent that moves from the black to the legal market is a progress. I’d rather have a legal and a black market than a 100 percent illegal market. If you take cigarettes as an example, there is also a black market, but there are no plans to prohibit cigarettes in order to rein that in.”
The right pricing will be decisive for deflating the illegal market, Wurth adds. “All three coalition partners are aware that they shouldn’t overplay their hand if they really want to force back the illegal market. I am confident that they will succeed if they find the right approach at pricing. In Canada, it took about two and a half years until half of the cannabis revenues came from the legal market.”
Illicit cannabis currently retails at €10 per gram in Germany. Interestingly, this is also the sales price for medicinal cannabis in pharmacies. “Cannabis already is relatively inexpensive in Germany,” says Adrian Fischer, co-founder and managing director of Demecan, which supplies medicinal cannabis. “We presume that consumers will be willing to pay a higher price for legal cannabis for recreational purposes that has a better quality than illegal weed, but the price shouldn’t be much higher than €10. In addition, it has to be guaranteed that there are a sufficient number of points of sale for marijuana. If a consumer must drive 50 kilometers to the next legal dispensary, he is more likely to stick with his dealer round the corner.” If legal cannabis is priced competitively, Fischer forecasts that the German marijuana market will be worth €5 billion in five years.
While the German Cannabis Organization opposes a limit on the THC content, Fischer suggests linking it to certain age limits, as with alcohol. In Germany, drinks with a low alcohol content, such as beer or wine, can be legally purchased from the age of 16 while liquor drinkers have to wait until they turn 18. “Similarly, cannabis with a lower THC content could be made available for 18-year-olds and with a higher THC content for 21-year-olds,” says Wurth.

Adrian Fischer
Important Considerations
The German Cannabis Organization believes the coalition should consider four aspects in shaping regulation. For starters, it should permit private cultivation for personal consumption. “In other countries that have legalized marijuana, such as Uruguay and some U.S. states, this is part of the law,” says Wurth.
Traffic laws are another issue. “Presently, limiting values and criminal proceedings are extremely strict. Cannabis users may lose their driver’s license even though they did not drive stoned, only because they have remainders of cannabis in their blood from consumption days ago that don’t have any effect on their driving behavior anymore,” says Wurth.
He also insists on an amnesty for the cannabis users who are currently listed as criminal offenders. “Their entries have to be deleted,” says Wurth. “In the U.S. states where marijuana is legal, this is regularly being done.”
Lastly, the sale of legal cannabis should remain restricted to specialist shops, according to the German Cannabis Organization. This would also guarantee better youth protection.
However, neither the legalization of cannabis for adults nor prohibition can prevent marijuana consumption among youths, cautions Wurth. “Legalization would nevertheless have a positive impact on youths, even though it cannot principally prevent youth consumption,” he says. “Youths are more susceptible to prevention measures, hence the latter should be stepped up significantly and reformed.
“Currently, police give preventive lessons in schools. They tend to get the message across that youths shouldn’t touch cannabis or else they would end up in the gutter, lose their driver’s licenses, etc. I hope that with the legalization there will also be more investment in better education and credible prevention measures so that youths seek drug counselling help earlier.”
If youths do consume cannabis, Wurth adds, it is safer if their older friends or siblings bring them legal weed from a licensed dispensary rather than potentially contaminated marijuana from a street dealer as is the case now.

Companies currently supplying medical cannabis say they will be able to scale up production rapidly when Germany legalizes recreational cannabis.
Gold Rush
The German illegal marijuana market is estimated at about 400 tons, most of which is imported from Morocco. Since Germany is a signatory to the 1961 United Nations Single Convention On Narcotic Drugs, the country will not be allowed to import or export cannabis for recreational purposes once the substance has been legalized. This means the coalition will either have to negotiate new conditions or stipulate that all cultivation has to take place in Germany.
Presently, only medicinal cannabis is grown in Germany. That business is controlled by three companies: Tilray, Aurora and Demecan. Under supervision of the state-owned cannabis agency, they jointly cultivate 2.6 tons of medicinal cannabis annually to cater to a market that is estimated at 12 tons to 15 tons per year, with demand increasing, according to Fischer. Due to the strict rules and standards, the companies grow the plants in hermetically sealed buildings, with product stored in high-security vaults. The first domestic crop reached pharmacies only last summer; a large amount of medicinal cannabis is still imported.
After legalization of recreational cannabis, manufacturers say they will be able to quickly expand production. Demecan has opened a center for medicinal cannabis in Ebersbach and recently finalized construction of Europe’s largest indoor marijuana production site. It presently has the capacity to produce 1 ton of medicinal cannabis but can supply 50 percent more at short notice, according to Fischer. “Within a year, we could step up capacity to 4 tons and in the mid-term to 10 tons per year. We are prepared to cater to growing demand. Our aim is to cultivate life quality and to ensure patient care, hence it is important to us that legalization of recreational cannabis doesn’t happen at the expense of patients. Therefore, we have built large production capacities to cater to both markets.”
The three providers of medicinal cannabis alone will nevertheless not be able to meet the demand for recreational cannabis, he admits. “To reach this target, legislature must tender licenses for the cultivation of marijuana in Germany relatively quickly and right on time before the actual legalization.”
With medicinal cannabis being a medicine, all aspects of production are subject to the narcotics act and must be compliant with good manufacturing practices and good agricultural and collection practices guidelines. A relaxation of production regulations for the cultivation of recreational weed, Fischer says, could contribute to less costly production.

Medicinal cannabis has been legal in Germany since 2017
Role Models
Wurth expects it to take another one or two years until the law takes effect—and even longer until the first licenses will be allocated, cultivation gets started and the first shops open. “The quickest part of such a law would be the decriminalization of consumers. The U.S. have shown that this can happen immediately.”
In shaping the law, he says, Germany has several role models it could draw upon. “The Netherlands are no example of a legalized market as the coffee shops are only tolerated, and supply is not regulated, so that criminal structures have emerged like everywhere else. But the coffee shops are a good example of allowing consumption on-site, which is not the case in most other countries that have legalized marijuana. As for points of sale, Germany should look to Canada and the U.S.—licensed specialist shops in a limited number; no access for youths; exact declaration of the products, their origins and their CBD and THC contents. Uruguay allows cultivation for personal use; people can even join grower communities to cultivate their weed or have it cultivated.”
In the end, the legalization of cannabis in Germany might go more smoothly, critics fear. In February 2021, the Cato Institute published a study on the legalization of marijuana by some U.S. states. It found that both proponents and opponents overstated their cases. Except for tax revenues, which exceeded some expectations, the report says state legalizations have mainly had minor effects.
Stefanie Rossel is Tobacco Reporter’s editorial contributor. An experienced trade journalist, she combines sharp reporting skills with in-depth knowledge of the tobacco and vapor industries. Prior to joining Tobacco Reporter, Stefanie was editor-in-chief at Tobacco Journal International, where she worked for a decade. Fluent in English, German and French, Stefanie covers tobacco news around the world. She is based in Germany.

February 1, 2022
Budding Business

Photo: Canadian Greenfield Technologies
The market for processing equipment is flourishing as more authorities legalize cannabis.
By Stefanie Rossel
If you think tobacco is a complex plant to handle, try processing cannabis. The plant consists of more than 100 cannabinoids, with each of them having a different effect on the body. In addition, it contains terpenes, naturally occurring chemical compounds that make certain strains taste or smell different than others.
The herb comes in two different varieties of the Cannabis sativa species: hemp and marijuana. Hemp is usually grown outdoors or in a greenhouse whereas marijuana is cultivated indoors or in a greenhouse.
The major difference between the two, however, is tetrahydrocannabinol (THC), a psychoactive constituent that produces the “high” people feel when they smoke marijuana or eat foods containing it. Hemp contains less than 0.3 percent THC whereas marijuana can have between 5 percent and 30 percent of the compound.
By contrast, the concentration of the nonpsychoactive component, cannabidiol (CBD), which is thought to have various therapeutic benefits, is high in hemp and low in marijuana. The latter species is grown for the highest concentrations of THC and CBD possible, with derivatives ranging from leafy material to THC and CBD extract and products such as candy or drinks. Hemp, on the other hand, is cultivated for CBD and other cannabinoids. It is the basis for CBD extracts, health foods and cosmetics. The stalks of hemp are used to create building materials, plastics, industrial oils, paper and textiles, among other products.
The global cannabis market was valued at $28.266 billion in 2021. With legalization gaining momentum, analysts predict unprecedented growth. Fortune Business Insights expects the global cannabis market to increase to $197.74 billion in 2028, reflecting a compound annual growth rate (CAGR) of 32.04 percent. In the U.S., the world’s leading market, where recreational cannabis is legal in nineteen states and the District of Columbia, the cannabis market was worth $13.5 billion in 2021, according to Grand View Research. Valued at $2.8 billion in 2020, the CBD segment is expected to expand to $13.4 billion in 2028, which corresponds to a CAGR of 21.2 percent. Grand View Research expects sales of hemp-derived CBD to grow even faster, at a CAGR of 23.4 percent post-pandemic due to increasing demand from the pharmaceutical sector and rising health awareness among consumers.
Separating the Green Fraction
Since recreational cannabis was legalized in Colorado a decade ago, a whole sector of dedicated, specialized processing equipment suppliers has emerged throughout the U.S. and Canada. Getting the desired compounds out of a marijuana or hemp plant is a complex, multi-step separation process.
In the case of hemp, it starts with the decortication of the tough woody interior or “hurd” material from the softer, fibrous exterior of the stalk. Depending on the size of their crop, farmers can outsource this procedure to third-party processors or do it themselves with specialized machinery. They can choose from equipment of various sizes, ranging from small mobile machines to industry-scale decorticators, such as the HempTrain, an advanced processing system developed by Canadian Greenfield Technologies Corp of Calgary. Conventional decorticator systems, which are based on a hammermill process, cause damage to the bast fiber and attrition to the hurd and are unable to separate the clean green fraction rich with CBD. The Hemp Train, by contrast, employs high-speed kinematic action, according to its manufacturer.
“The HempTrain is indeed a mini factory,” explains Stephen Christensen, vice president of Canadian Greenfield Technologies Corp. “HempTrains use our patented advanced processing technologies in two different modes: a) to separate dry feedstock into long, structural bast fiber, clean, size-specific hurd, and a nutrient-rich microfiber, and b) to separate fresh/green feedstock into a high-CBD fraction containing bud leaves and a lower CBD fraction containing all other material. Bearing this in mind, the typical target groups would be general hemp processors, or product specific producers—including CBD from industrial hemp or other hemp streams. This is not available from any other technologies.”
The company, which sells its equipment in the U.S. and Canada, is in the process of licensing its technology to an African company to manufacture and distribute its decortication technology and equipment in eight African countries, the U.K. and the Caribbean. Christensen says that currently the U.S., Eastern Europe, Southern Africa and Australia account for the most international interest as these countries have been the most successful in educating their people and governments about the benefits of whole-plant utilization.
Multi-Step Procedure
In the next step, the biomass undergoes an extraction process, during which it is placed inside an extraction vessel with a solvent to remove soluble components.
“There are three primary methods of extracting hemp and cannabis: CO2, ethanol and light hydrocarbons, propane and butane,” explains Fritz Chess, founder Eden Labs, a supplier of cannabis extraction equipment based in Seattle. “All of these methods have their pros and cons. CO2 has the advantage of being a nonflammable, solventless method that also has great marketing cachet. Once the equipment is paid for, it is also the lowest cost method, which means in the long run, CO2 will likely rule the industry. Initial costs for CO2 are much higher than the other two methods—up to 10 times as much.”
Ethanol has the lowest cost of entry, he adds, but involves a multi-step process using large volumes of a flammable liquid.
In many ways, hydrocarbons are the most efficient method, Chess says. “It’s a very fast extraction and requires less post-processing than other methods. Equipment costs are less than the other two methods. The problem is the extreme flammability of these gases adds an enormous burden of safety requirements and regulations, which can negate the cost advantage of the equipment purchase.”
With all three methods, the desired constituents cannabinoids and terpenes, which have value for medicinal and recreational use, can be extracted simultaneously. “Flowers and leaves are the part of the plant that is extracted, with flowers being the most desirable,” Chess points out.
His company has been on the market longer than most other players in the field. It was established in 1994 as a manufacturer of plant botanical extraction but began to include cannabis extraction early on. Meanwhile, the latter generates the majority of his company’s turnover, Chess says. “When proposition 215 passed in California [permitting cannabis] for medical use, cannabis became about 20 percent of Eden Labs’ business. When recreational [use] passed in Washington and Denver, it went to about 80 percent, and the company doubled sales for three consecutive years.”
Eden Labs supplies extraction equipment using CO2 and ethanol but occasionally builds custom hydrocarbon extractors, says Chess. A recent solution by the company combines the advantages of the two solvents CO2 and hydrocarbon, catering to both marijuana and hemp companies. The machines are making use of the higher output achieved by hydrocarbon extraction while at the same time reducing the danger of flammability by diluting the hydrocarbon with CO2. “We have a method combining CO2 and a small percentage of propane, which has the advantages of making a very high-quality extract quickly in a process that is nonflammable. We are currently marketing this design to select customers.”
Refining Exercise
After extraction, the liquid obtained from extraction, which contains cannabinoids, THC and/or CBD, waxes, fats, lipids and terpenes, must be winterized. During this procedure, proof alcohol is added to the oil to thin it and causes the fats, waxes and lipids to coagulate. The consecutive filtration separates them from the oil.
After that, the liquid undergoes solvent recovery, during which the majority of solvent in the crude cannabis extract is removed and the cannabinoids are separated from the solvent. High-speed evaporators help accelerate the process.
The liquid is then filled into a reactor, chiller, condenser or vacuum pump for decarboxylation, a chemical process that converts THCA and CBDA, the biosynthetic precursors of THC and CBD, into THC and CBD via heating and drying. This procedure can take up to ten hours.
Finally, distillation will further refine the cannabis extract. Through vacuum-assisted evaporation, the cannabinoids are separated from impurities, such as terpenes and plant material. The extract is heated and each of the undesired components separated due to their different boiling points.
As ever more countries legalize cannabis for medicinal and recreational use, Chess has a clear vision of how the market will develop. “As cannabis legalizes globally and an import/export market forms, we expect the same market forces to come into play that used to rule the black market. Tropical regions will once again dominate the market because of the longer growing season and superior product that comes from that part of the world. The expensive indoor grows that currently dominate the market will be priced out of existence.”
Stefanie Rossel is Tobacco Reporter’s editorial contributor. An experienced trade journalist, she combines sharp reporting skills with in-depth knowledge of the tobacco and vapor industries. Prior to joining Tobacco Reporter, Stefanie was editor-in-chief at Tobacco Journal International, where she worked for a decade. Fluent in English, German and French, Stefanie covers tobacco news around the world. She is based in Germany.

February 1, 2022
22nd Century, Aurora and Cronos License Biosynthesis IP

Photo: contentdealer
Aurora Cannabis together with 22nd Century Group announced a three-way nonexclusive agreement to license biosynthesis intellectual property to Cronos Group, intended to assist in the advancement of research and development on the biosynthesis of cannabinoids.
“We are deeply interested in the evolution of cannabinoids, and this is a promising step toward the commercialization of cannabinoid products using biosynthesis,” said Miguel Martin, CEO of Aurora. “The long-term potential for rare cannabinoid molecules produced through biosynthesis is incredibly promising given their efficient production methods and potential therapeutic benefits and utility in health, wellness and consumer products.”
“This license combines the resources and intellectual property of all three companies in this agreement intended to facilitate the commercial success of a biosynthetic approach, which complements the disruptive plant-based advancements 22nd Century and Aurora continue to develop to bring more consistent and higher yields to the hemp and cannabis industry,” said James A. Mish, CEO of 22nd Century Group, in a statement. “We believe that the availability of both plant-based and biosynthetic cannabinoids will be important to the commercial success of our industry, and this agreement positions 22nd Century, Aurora and Cronos Group with an important role in each approach.”
“Cronos Group has successfully commercialized the first cultured cannabinoid product in Canada. Licensing this intellectual property provides us with a component of the process that could allow for increased speed and efficiency in the development and commercialization of cultured cannabinoids,” said Kurt Schmidt, president and CEO of Cronos Group.

December 15, 2021
ReCreation Marketing Becomes Turning Point Brands Canada

ReCreation Marketing will be known and operate as Turning Point Brands Canada effective Dec. 6, 2021.
The name change follows a transaction that resulted in Turning Point Brands increasing its equity stake in ReCreation Marketing to a majority position. The transaction was completed on July 30, 2021.
“ReCreation Marketing changing its name to Turning Point Brands Canada reflects our commitment to our shared values with TPB and to expanding the exposure and reach of iconic core brands, such as Zig-Zag, in Canada,” said Mikail Fancy, chief operating officer of Turning Point Brands Canada, in a statement. “TPB Canada is laser-focused on creating value directly with, and for, our partners by offering a portfolio of recognized, differentiated, consumer-relevant brands and products.”
Turning Point Brands Canada continues to focus its resources on being a leader in the cannabis accessory category in Canada by fostering long-term, growth-oriented partnerships with manufacturers and retailers.
“The rebrand of ReCreation Marketing to TPB Canada is a testament to our confidence in the ReCreation management team and is a natural extension of our infrastructure and portfolio development that puts consumers and their evolving needs at the center of our strategy,” added Larry Wexler, CEO of Turning Point Brands. “This change further demonstrates our commitment to positioning TPB as a leader in branded consumer products.”
December 6, 2021
Tobacco Authority of Thailand Creates Hemp Subsidiary

Photo: kittyfly
The Tobacco Authority of Thailand (TOAT) plans to set up a subsidiary to move into the hemp business, reports The Bangkok Post, citing the state enterprise’s governor, Phanupol Rattanakanjanapatra. The project aims to triple or quadruple tobacco farmers’ incomes.
On Sept. 28, the TOAT signed a memorandum of understanding for hemp business with Santa Fe Farms (Thailand) Co., a subsidiary of Santa Fe Farms LLC in the United States.
Phanupol expects the State Enterprise Policy Office to approve the TOAT’s ambitions in the hemp business within the next couple of months.
TOAT sells 18 billion cigarettes per year. However, a 2017 cigarette excise tax hike has hurt many of its farmers by depressing sales and shrinking the TOAT’s tobacco-buying quota.
The hemp project is intended to help offset farmers’ lower tobacco sales.
September 29, 2021
Turning Point Brands Invests in Old Pal Cannabis Brand

Photo: yellowj
Turning Point Brands (TPB) has completed an $8 million strategic investment in Old Pal Holding Co. through a convertible note that includes follow-on investment rights.
Founded in 2018 by Rusty Wilenkin and Jason Osni, Old Pal is a leading cannabis brand that operates a nonplant touching licensing model and sells its products to consumers across the U.S.
TPB’s investment will enable Old Pal to expand product offerings in existing states, which include California, Nevada, Michigan, Oklahoma, Ohio, Washington and Massachusetts, and will help create the infrastructure necessary to support continued territory and product expansion. As a result of Old Pal’s strong brand recognition and extensive network of licensed cultivation and production relationships, the company has the ability to scale its geographic footprint while continuing to offer consistent and readily available products, according to TPB.
“Turning Point has a proven track record of developing and growing brands and is capitalizing on this experience to identify highly recognizable leading cannabis brands poised to experience significant growth,” said Larry Wexler, CEO of Turning Point Brands, in a statement. “Given Old Pal’s favorable market position, the awareness of its products outside its current geographies and its unique licensing model, we are confident the brand is well-positioned to further penetrate the market and capitalize on the growth potential of the cannabis industry.”
“Old Pal’s mission is to spread the shareable cannabis lifestyle to customers across the U.S. through accessible and high-quality products,” added Charlie Cangialosi, chief operating officer at Old Pal. “Turning Point Brands’ experience with iconic brands, like Zig-Zag, and success in adjacent and complementary industries will allow us to bring the Old Pal experience to a wider range of markets and consumers.”
July 23, 2021